Bradley Foster & Sargent Inc. CT Sells 1,336 Shares of Amgen Inc. $AMGN

Bradley Foster & Sargent Inc. CT reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,414 shares of the medical research company’s stock after selling 1,336 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Amgen were worth $4,068,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 2nd quarter valued at $27,000. Evelyn Partners Investment Management LLP bought a new position in shares of Amgen in the second quarter valued at $32,000. Howard Hughes Medical Institute bought a new position in shares of Amgen in the second quarter valued at $32,000. Quaker Wealth Management LLC grew its holdings in shares of Amgen by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares during the last quarter. Finally, Cloud Capital Management LLC bought a new stake in shares of Amgen during the third quarter worth about $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.4%

Shares of Amgen stock opened at $384.33 on Thursday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $387.49. The firm has a market cap of $207.18 billion, a PE ratio of 27.01, a P/E/G ratio of 3.79 and a beta of 0.46. The stock has a fifty day moving average price of $346.58 and a 200-day moving average price of $318.34. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. Amgen’s payout ratio is presently 70.84%.

Analysts Set New Price Targets

A number of research firms have issued reports on AMGN. Scotiabank assumed coverage on Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target for the company. Rothschild & Co Redburn raised their target price on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Leerink Partners upped their price target on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Finally, Argus lifted their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $351.76.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.